We have observed
3 EP applications
has served for within the last five+ years.
(We consider all applications which have an EP A1 publication dated after
December 17, 2012).
Please note, that we only count EP applications,
in which the name of the patent attorney is explicitly mentioned as representative.
These EP applications are:
OPHTHALMIC COMPOSITIONS COMPRISING PROSTAGLANDIN F2 ALPHA DERIVATIVES AND HYALURONIC ACID
THIENOPYRIDONE DERIVATIVES USEFUL AS ACTIVATORS OF AMPK
FUNCTIONAL OR TELECHELIC POLYOLEFIN, DERIVATIVES THEREOF, AND PROCESS FOR PREPARING SAME